Author

Glenn C. Michelson

Observed names: G C Michelson, G. C. Michelson, G. Michelson, G.C. Michelson, Glenn C Michelson, Glenn Michelson, glenn C michelson

Observed institutions: BC Cancer Agency, City Of Hope National Medical Center, Mayo Clinic, Memorial Sloan Kettering Cancer Center, University of Louisville, Emory University, University of New Mexico, University of Pittsburgh, Duke University, Genentech, Loyola University Chicago, Juravinski Cancer Centre, Beatson West of Scotland Cancer Centre, Institut Gustave Roussy, Moffitt Cancer Center, University of Alabama at Birmingham, University of Chicago Medical Center, Portola Pharmaceuticals (United States), City of Hope, Dana-Farber Cancer Institute, Royal Marsden Hospital, Mayo Clinic in Arizona, Notable Labs (United States), Sylvester Comprehensive Cancer Center, Loyola Medicine, Sidney Kimmel Comprehensive Cancer Center, Cogent Biosciences (United States), Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Chicago Medicine Comprehensive Cancer Center, Plexxikon (United States), Audentes Therapeutics (United States), Indiana University, Sunesis (United States), Institut Curie, Stanford University

OpenAlex ID: A5083215091

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

2008 · Debashis Sarker, Rhoda Molife, et al. · Clinical Cancer Research · 138

PDF

A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma

2006 · Khuda D. Khan, Christos Emmanouilides, et al. · Clinical Cancer Research · 99

PDF

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive, Locally Advanced, or Metastatic Breast Cancer

2014 · Kathy D. Miller, Véronique Diéras, et al. · Journal of Clinical Oncology · 86

Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors

2021 · Andrew J. Wagner, Paul L. Severson, et al. · JAMA Oncology · 44

PDF

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

2011 · J E Lancet, F Ravandi, et al. · Leukemia · 44

PDF

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

2018 · Greg P. Coffey, Jiajia Feng, et al. · Clinical Cancer Research · 40

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

2019 · Steven M. Horwitz, Tatyana A. Feldman, et al. · Blood · 37

Phase ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.

2018 · Amita Patnaik, Richard D. Carvajal, et al. · Journal of Clinical Oncology · 32

Interleukin-2 associated linear IgA bullous dermatosis

1996 · A. Tranvan, D.S. Pezen, et al. · Journal of the American Academy of Dermatology · 32

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B‐cell malignancies: Results of a phase I study

2018 · Paul A. Hamlin, Ian W. Flinn, et al. · American Journal of Hematology · 31

REVEAL ‐1, a phase 2 dose regimen optimization study of vosaroxin in older poor‐risk patients with previously untreated acute myeloid leukaemia

2014 · Robert K. Stuart, Larry D. Cripe, et al. · British Journal of Haematology · 31

PDF

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

2014 · J. E. Lancet, G. J. Roboz, et al. · Haematologica · 28

PDF

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

2018 · Steven M. Horwitz, Tatyana A. Feldman, et al. · Blood · 25

Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.

2023 · Macarena Ines De La Fuente, Jordi Rodon Ahnert, et al. · Journal of Clinical Oncology · 23

Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies

2004 · G. M. Springett, C. Takimoto, et al. · Journal of Clinical Oncology · 23

Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer

2011 · Lee M. Krug, Jeffrey Crawford, et al. · Journal of Thoracic Oncology · 20

PDF

A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients

2009 · F. Robert, C. Verschraegen, et al. · Journal of Clinical Oncology · 16

Phase 1/2 precision medicine study of the next-generation BRAF inhibitor PLX8394.

2018 · Filip Janku, Ulka N. Vaishampayan, et al. · Journal of Clinical Oncology · 13

Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules.

2010 · R. K. Stuart, F. Ravandi Kashani, et al. · Journal of Clinical Oncology · 11

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST).

2018 · Andrew J. Wagner, William D. Tap, et al. · Journal of Clinical Oncology · 9

Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.

2010 · G. J. Roboz, J. E. Lancet, et al. · Journal of Clinical Oncology · 9

A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

2009 · Farhad Ravandi, Hagop M. Kantarjian, et al. · Blood · 8

Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma

1999 · Todd M. Zimmerman, Glenn C. Michelson, et al. · Journal of Clinical Apheresis · 8

Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients.

2009 · Jeffrey E Lancet, Gail J. Roboz, et al. · Blood · 7

Trls-02. Safety and Efficacy of Braf Inhibitor Plixorafenib (fore8394; Plx8394) in Children and Adults With Recurrent, Braf-altered Primary Central Nervous System Tumors (pcnst)

2024 · Macarena de la Fuente, Nicholas A Butowski, et al. · Neuro-Oncology · 6

PDF

Works count: 74

Citation count: 916

H-index: 16

I10-index: 19